Which of your patients are ‘not candidates for local oestrogens’?

The recent approval of Senshio®, 60mg ospemifene, for the indication treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy [1] is a valuable addition to the armamentarium for doctors to treat vulvo-vaginal atrophy. This is the first non-hormonal oral product to be licensed for this indication. Senshio® (60mg ospemifene) is a Selective Oestrogen Receptor Modulator (SERM). There are various SERMs available for different indications (treatment of breast cancer: tamoxifen and toremifene, treatment of osteoporosis: raloxifene and bazedoxifene, and treatment of infertility: clomiphene), but they all have in common that they antagonise the effect of oestrogen in some tissues and can mimic the effect of oestrogen in other tissues, particularly in the absence of oestrogens.
Source: Maturitas - Category: Primary Care Authors: Tags: LBN 20 Source Type: research